Literature DB >> 27867976

Sofosbuvir and velpatasvir: a stellar option for patients with decompensated hepatitis C virus (HCV) cirrhosis.

Joel V Chua1, Shyam Kottilil1.   

Abstract

Entities:  

Year:  2016        PMID： 27867976      PMCID： PMC5104658          DOI： 10.21037/atm.2016.08.56

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

Review 2.  Hepatitis C genotype 3 disease.

Authors:  Sarah Kattakuzhy; Rachel Levy; Elana Rosenthal; Lydia Tang; Eleanor Wilson; Shyam Kottilil
Journal:  Hepatol Int       Date:  2016-06-21       Impact factor: 6.047

3.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-06

Review 4.  Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease.

Authors:  Sabela Lens; Zoe Mariño; Xavier Forns
Journal:  Dig Liver Dis       Date:  2014-11-06       Impact factor: 4.088

Review 5.  Natural history of hepatitis C.

Authors:  Rachel H Westbrook; Geoffrey Dusheiko
Journal:  J Hepatol       Date:  2014-11-03       Impact factor: 25.083

6.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.

Authors:  Fred Poordad; Eugene R Schiff; John M Vierling; Charles Landis; Robert J Fontana; Rong Yang; Fiona McPhee; Eric A Hughes; Stephanie Noviello; Eugene S Swenson
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

7.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Authors:  Graham R Foster; Nezam Afdhal; Stuart K Roberts; Norbert Bräu; Edward J Gane; Stephen Pianko; Eric Lawitz; Alex Thompson; Mitchell L Shiffman; Curtis Cooper; William J Towner; Brian Conway; Peter Ruane; Marc Bourlière; Tarik Asselah; Thomas Berg; Stefan Zeuzem; William Rosenberg; Kosh Agarwal; Catherine A M Stedman; Hongmei Mo; Hadas Dvory-Sobol; Lingling Han; Jing Wang; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Francesco Mazzotta; Tram T Tran; Stuart C Gordon; Keyur Patel; Nancy Reau; Alessandra Mangia; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-11-17       Impact factor: 91.245

8.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

9.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

10.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal
Journal:  J Hepatol       Date:  2016-01-30       Impact factor: 30.083
View more
  2 in total

1.  Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients.

Authors:  John Romano; Omar T Sims; Joshua Richman; Yuqi Guo; Tasnia Matin; Mohamed Shoreibah; Vishnu Kommineni; Krishna Venkata; Omar I Massoud
Journal:  JGH Open       Date:  2018-09-19

2.  Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.

Authors:  Yeo Wool Kang; Yang Hyun Baek; Sung Wook Lee; Sung Jae Park; Jun Sik Yoon; Ki Tae Yoon; Youngmi Hong; Nae Yun Heo; Kwang Il Seo; Sang Soo Lee; Hyun Chin Cho; Jung Woo Shin
Journal:  J Korean Med Sci       Date:  2021-05-31       Impact factor: 2.153
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.